Treatment for dementia

Current situation: Dementia affects 5 per cent of people over the age of 65 years, and 20 per cent of those aged over 80 years in the UK.

The three cholinesterase inhibitors — donepezil, rivas-tigmine and galantamine — are currently all recommended for use in patients with Alzheimer’s disease. New NICE guidance will be finalised next month.

What is the evidence?

Evidence from randomised controlled trials (RCT) has shown that these drugs have beneficial effects on cognitive and global outcome measures.

However, a recent systematic review of 22 RCTs has shown that the scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer’s is questionable (BMJ 2005; 331: 321).

Although the outcomes measuring cognition did show beneficial effects of cholines-terase inhibitors, these effects were minimal. The review found that the methodological quality of the available trials was poor.

The results of an RCT that compared both donepezil and vitamin E against placebo were deeply disappointing (N Engl J Med 2005; 352: 2379). Although an initial benefit of donepezil was seen during the first year, it was not sustained.

One study has shown that patients with dementia are now being referred earlier to specialists, which has led to more cholinesterase inhibitors being prescribed (Psychiatric Bulletin 2006; 30: 131).

Some experts believe memory clinics have spent time and money monitoring patients on cholinesterase inhibitors rather than actually ensuring the delivery of multidisciplinary care plans (BMJ 2006; 333: 491).

Various meta-analyses have shown quite consistently that these medicines have modest beneficial effects compared with placebo (Cochrane Database Syst Rev 2006; (1): CD001190, and Health Technol Assess 2006; 10: 1).

Implications for practice

When NICE adjusted costs to take account of the benefits attributed to these drugs it estimated that donepezil, rivastigmine, and galantamine had a cost per quality-adjusted life year gained of £48,000, £32,000, and £38,000 respectively.

Draft NICE guidance issued in January 2006 recommends that cholinesterase inhibitors should be considered in the treatment of patients with moderately severe disease but not for those patients who have milder symptoms.

If the proposed recommendations by NICE are adopted, the NHS would save £15 million in the first year, £45 million in the second, and more than £60 million in the third.

NICE has rejected appeals against initial guidance. The final guidance will be issued next month.

Useful websites

www.nice.org.uk — NICE

www.Alzheimers.org.uk — Alzheimer’s Society

Dr Louise Newson is a GP in the West Midlands and author of ‘Hot Topics for MRCGP and General Practitioners’, Pas Test 2006

Key points

Dementia is very common.

Cholinesterase inhibitors may be less effective than initially thought.

NICE guidelines may change in the near future.

The appropriate use of cholinesterase inhibitors in Alzheimer’s disease is controversial.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP consultations up 400,000 in first three weeks of 2021 compared with last year

GP consultations up 400,000 in first three weeks of 2021 compared with last year

GPs have delivered around 400,000 more patient consultations in the first three full...

GPs vaccinate thousands of patients against COVID-19 in extraordinary settings

GPs vaccinate thousands of patients against COVID-19 in extraordinary settings

GPonline takes a look at some of the more interesting sites that have played host...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

GPs to place orders for COVID-19 vaccine as NHS targets second dose at 12 weeks, says Stevens

GPs to place orders for COVID-19 vaccine as NHS targets second dose at 12 weeks, says Stevens

GP-led vaccination sites will be able to place orders for COVID-19 vaccine supplies...

RCGP and Marie Curie urge GPs to adopt end of life care standards for care homes

RCGP and Marie Curie urge GPs to adopt end of life care standards for care homes

Best practice standards to help GPs improve end of life care in care homes despite...

Thank your team for their inspirational work during the COVID-19 pandemic #myGPteam

Thank your team for their inspirational work during the COVID-19 pandemic #myGPteam

Never has teamwork in general practice been more important than during the COVID-19...